• Pharmaceutical companies are stockpiling medicines due to ongoing uncertainty over what will happen in Northern Ireland after Brexit.
  • The UK government last month threatened to rip up its Brexit withdrawal agreement with the EU and has warned that no trade deal may be agreed with the EU by the end of the year.
  • As a result, the industry says they “just don’t know” whether there will need to be checks on medicine going from Great Britain to Northern Ireland from next year.
  • “We just don’t know how it’ll work in Northern Ireland,” the ABPI’s Richard Torbett told Business Insider.
  • Visit Business Insider’s homepage for more stories.

Pharmaceutical companies are building up stockpiles of medicines to supply Northern Ireland due to widespread industry uncertainty over whether medicines will be allowed to move smoothly across the Irish Sea after Brexit.

With less than three months until the Brexit transition period ends, the

Read More



Mayor press conference

Mayor Leirion Gaylor Baird speaks with Lincoln-Lancaster County interim health director Pat Lopez during a meeting on Wednesday.




Recovering from an illness comes in two stages.

First, one battles the symptoms to ease the immediate pain. Second, one regains strength to return to normal activity. And, maybe, in that recovery process, one finds himself or herself better prepared for the next illness.

That same process is the underpinning for the document released last week by the Mayor’s Economic Recovery Task Force. Presented by Mayor Leirion Gaylor Baird and co-chairs Angie Muhleisen, president and CEO of Union Bank & Trust, and Ava Thomas, president and publisher of the Journal Star, the plan focuses on the strengths of our community and the tools we have

Read More

Aziyo Biologics, which makes regenerative medical products for various tissue types, filed on Monday with the SEC to raise up to $58 million in an initial public offering.

Through its proprietary tissue processing platforms, the company has developed a portfolio of advanced regenerative medical products designed to be similar to natural biological material. Its core products are designed to address the implantable electronic device/cardiovascular, orthopedic/spinal repair, and soft tissue reconstruction markets. 

The Silver Spring, MD-based company was founded in 2015 and booked $42 million in revenue for the 12 months ended June 30, 2020. It plans to list on the Nasdaq under the symbol AZYO. Aziyo Biologics filed confidentially on July 10, 2020. Piper Sandler, Cowen, Cantor Fitzgerald and Truist Securities are the joint bookrunners on the deal. No pricing terms were disclosed.

The article Regenerative medicine company Aziyo Biologics files for a $58 million IPO originally appeared on

Read More